Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized multicenter study of yinfenidone hydrochloride tablets in idiopathic pulmonary fibrosis
CTR20210132Phase 2Active
- Sponsor
- HEC Pharm
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of yifenidone in idiopathic pulmonary fibrosis (IPF), sponsored by HEC Pharm. Started Aug 2021; status: active.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20210132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210132.